Table A3.
SIRs for SMNs After 40 Years of Age for Cohort Members Not Treated With Previous Irradiation
| Cohort Members Not Treated With Previous Irradiation* |
||||||||
|---|---|---|---|---|---|---|---|---|
| No SN Before 40 Years of Age |
SN Before 40 Years of Age |
|||||||
| Characteristics | Observed | Expected | SIR (95% CI) | EAR | Observed | Expected | SIR (95% CI) | EAR |
| All patients | 28 | 21.4 | 1.3 (0.9 to 1.9) | 0.34 | 2 | 1.5 | 1.3 (0.3 to 5.0) | 0.35 |
| Sex | ||||||||
| Male | 9 | 9.4 | 1.0 (0.5 to 1.8) | −0.04 | 0 | |||
| Female | 19 | 12 | 1.6 (1.0 to 2.6) | 0.77 | 2 | 1.1 | 1.7 (0.5 to 6.6) | 1.03 |
| Primary cancer diagnosis | ||||||||
| Leukemia | 8 | 2.8 | 2.9 (1.4 to 6.0) | 1.75 | 1 | 0.3 | 3.2 (0.6 to 18.2) | 2.58 |
| CNS malignancy | 3 | 2.4 | 1.3 (0.3 to 5.1) | 0.25 | 0 | |||
| Hodgkin lymphoma | 0 | 0 | ||||||
| Non-Hodgkin lymphoma | 3 | 1.6 | 1.8 (0.6 to 5.5) | 0.86 | 0 | |||
| Wilms tumor | 0 | 0 | ||||||
| Neuroblastoma | 0 | 0 | ||||||
| Soft tissue sarcoma | 3 | 4.3 | 0.7 (0.2 to 2.1) | −0.38 | 0 | |||
| Bone cancer | 11 | 8.7 | 1.3 (0.7 to 2.3) | 0.31 | 1 | 0.6 | 1.8 (0.3 to 12.0) | 0.93 |
| Type of SMN | ||||||||
| Breast | 13 | 4.3 | 3.0 (1.6 to 5.5) | 0.45 | 0 | |||
| Thyroid | 0 | 0 | ||||||
| Soft tissue sarcoma | 3 | 1.2 | 2.5 (0.8 to 7.6) | 0.09 | 0 | |||
| Osteosarcoma | 0 | 0 | ||||||
| CNS malignancy | 0 | 0 | ||||||
| Lymphoma | 1 | 2.2 | 0.5 (0.1 to 3.2) | −0.06 | 0 | |||
| Melanoma | 5 | 2.1 | 2.3 (1.0 to 5.6) | 0.15 | 0 | |||
| Leukemia | 1 | 0.6 | 1.6 (0.2 to 11.6) | 0.02 | 0 | |||
| Lung | 0 | 0 | ||||||
| Female genitourinary | 2 | 1.8 | 1.1 (0.3 to 4.4) | 0.02 | 1 | 0.2 | 5.7 (0.9 to 38.3) | 1 |
| Head and neck | 1 | 0.7 | 1.5 (0.2 to 10.7) | 0.02 | 1 | 0 | 27.0 (3.8 to 191.4) | 0.74 |
| Renal | 2 | 0.6 | 3.6 (0.9 to 14.2) | 0.07 | 0 | |||
| GI | 0 | 0 | ||||||
| Other | 0 | 0 | ||||||
| Treatment exposure | ||||||||
| Alkylating agents | 16 | 9.6 | 1.7 (1.0 to 2.8) | 0.72 | 1 | 0.7 | 1.4 (0.2 to 9.5) | 0.44 |
| Anthracyclines | 17 | 9.6 | 1.8 (1.1 to 2.9) | 0.83 | 1 | 0.7 | 1.5 (0.2 to 10.0) | 0.53 |
| Epipodophyllotoxins | 0 | 0 | ||||||
| Platinum | 3 | 1.5 | 2.1 (0.7 to 6.3) | 1.03 | 1 | 0 | 21.8 (9.6 to 49.4) | 22.37 |
| Chemo | 20 | 14.1 | 1.4 (0.9 to 2.2) | 0.45 | 2 | 1 | 1.9 (0.5 to 7.2) | 1.06 |
| No chemotherapy | 8 | 7.3 | 1.1 (0.5 to 2.3) | 0.11 | 0 | |||
Abbreviations: EAR, excess absolute risk per 1,000 person-years; SIR, standardized incidence ratio; SMN, subsequent malignant neoplasm; SN, subsequent neoplasm.
*
Total number of observed events in the with- and without-previous radiation groups is 186; for 10 SMNs, the radiation status of the individual was unknown.